The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. - Trial NCT06140576
Access comprehensive clinical trial information for NCT06140576 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Zhejiang Cancer Hospital and is currently Not yet recruiting. The study focuses on Breast Neoplasms. Target enrollment is 58 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zhejiang Cancer Hospital
Timeline & Enrollment
Phase 1/2
Nov 30, 2023
Dec 31, 2026
Primary Outcome
safety and tolerability,Objective Response Rate (ORR)
Summary
The treatment regimen of lenvatinib combined with PD1 antibody has brought earth shaking
 changes to the immunotherapy of various cold tumors. This is a phase Ib/IIa clinical trial
 to investigate the efficacy and safety of Lenvatinib combined with Sindilimab and
 Nab-paclitaxel in the first-line treatment for recurrent and metastatic triple negative
 breast cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06140576
Non-Device Trial